Sarraju, AshishLi, JingWeiCannon, Christopher P.Chang, Tara I.Agarwal, RajivBakris, GeorgeCharytan, David M.de Zeeuw, DickGreene, TomHeerspink, Hiddo J. L.Levin, AdeeraNeal, BrucePollock, CarolWheeler, David C.Yavin, YshaiZhang, HongZinman, BernardPerkovic, VladoJardine, MegMahaffey, Kenneth W.2024-08-122024-08-122021Sarraju A, Li J, Cannon CP, et al. Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. Am Heart J. 2021;233:141-148. doi:10.1016/j.ahj.2020.12.008https://hdl.handle.net/1805/42729We aimed to assess the efficacy and safety of canagliflozin in patients with type 2 diabetes and nephropathy according to prior history of heart failure in the Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation (CREDENCE) trial. We found that participants with a prior history of heart failure at baseline (15%) were more likely to be older, female, white, have a history of atherosclerotic cardiovascular disease, and use diuretics and beta blockers (all P < .001), and that, compared with placebo, canagliflozin safely reduced renal and cardiovascular events with consistent effects in patients with and without a prior history of heart failure (all efficacy P interaction >.150). These results support the efficacy and safety of canagliflozin in patients with type 2 diabetes and nephropathy regardless of prior history of heart failure.en-USPublisher PolicyAdrenergic beta-antagonistsCanagliflozinHeart failureSodium-glucose transporter 2 inhibitorsDiureticsArticle